2002-08-08
org.kosen.entty.User@39d44549
박민식(lshtm)
발행기관
Roger Ulrich and Stephen H. Friend
발행일
2002. 1.
첨부파일
Acting on reports in the late 1980s that most
drug candidates fail in development,
pharmaceutical discovery programmes
responded by devising ways to increase the
number of chemicals in the pipeline. With
discovery now driven primarily by chemistry
and high-throughput screening, the biological
effects and, in particular, the toxicity of new
compounds are largely not appreciated until
a compound enters development. Arguably,
this paradigm has produced more failures
rather than delivering more successes ？
with more chemicals to examine, much less
is known about any single agent before costly
development studies are initiated. The
emerging field of toxicogenomics is enabling
us to ask detailed questions about drug
effects very early on, thereby fundamentally
changing our approach to drug discovery.
-
리포트 평점
해당 콘텐츠에 대한 회원님의 소중한 평가를 부탁드립니다. -
0.0 (0개의 평가)